Healthcare entity
All 1 tracked stories fall under one category: market-trends. Bluebird Bio is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 6 in the same window.
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Bluebird Bio is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 6 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Healthcare story that mention Gene Therapy, all published on February 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Gene Therapy. Shared-story counts are live from our verified record — not editorial picks.
While gene therapies offer unprecedented curative potential for rare and chronic diseases, high costs and logistical hurdles are creating a significant access gap in the U.S. healthcare system. This briefing examines the systemic challenges preventing widespread adoption and the emerging financial models designed to bridge the divide.
Gene Therapy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
